David Amsellem

Ram Selvaraju

Jeff Hung

Stacy Lee

Yale Jen

Annabel Samimy

Annabel Sammy

- Evofem Biosciences, Inc. stockholders **did not approve** the proposal to adopt the Amended and Restated Merger Agreement with Aditxt, Inc. at a Special Meeting of Stockholders held on **October 20, 2025**.  **[1618835_0001493152-25-018687_ex99-1.htm:0]** **[1618835_0001493152-25-018687_form8-k.htm:1]** 
- As a result, Evofem **exercised its rights to terminate the Merger Agreement** effective **October 20, 2025**.  **[1618835_0001493152-25-018687_ex99-1.htm:0]** **[1618835_0001493152-25-018687_form8-k.htm:1]** 
- The company will now **pivot to focus on regaining a national listing** for its stock and **securing capital** to catalyze growth, with a goal of achieving sustainable positive EBITDA in **2027**.  **[1618835_0001493152-25-018687_ex99-1.htm:0]** 
- For the merger proposal, there were **93,239,872 votes For** and **7,208,466 votes Against**.  **[1618835_0001493152-25-018687_form8-k.htm:2]**

Evofem Stockholders Reject Aditxt Merger, Company Terminates Agreement

- Evofem Biosciences' stockholders **did not approve the merger with Aditxt**, leading to the termination of the Merger Agreement.  **[1618835_20251020LA02477:0]** 
- The company is now pivoting to focus on **regaining a national listing for its stock** and securing growth capital, with a goal to achieve sustainable positive EBITDA in **2027**.  **[1618835_20251020LA02477:0]** 
- Evofem will continue its collaboration with Aditxt to commercialize Mitomic™ diagnostic tests for women's health.  **[1618835_20251020LA02477:0]** 
- Evofem commercializes two FDA-approved sexual health products, PHEXXI® and SOLOSEC®, and reported its **fourth consecutive year of net sales growth in 2024**.  **[1618835_20251020LA02477:0]**

Evofem Stockholders Reject Aditxt Merger, Company Pivots to National Listing and Growth Capital

- Evofem Biosciences announced the conclusion and impact of its August 2025 "Say Vagina" campaign, which generated over **2.5 million views** across social media platforms and led to a **130% increase** in traffic to PHEXXI.com.  **[1618835_20250911LA71451:0]** 
- The campaign also resulted in PHEXXI® becoming the **#1 most followed contraceptive brand** on social media by healthcare providers.  **[1618835_20250911LA71451:0]** 
- Evofem plans to launch SayVaginaStore.com in September, with **100% of proceeds** from Say Vagina Month items donated to charity.  **[1618835_20250911LA71451:0]** 
- The company filed a Definitive Proxy on September 8, 2025, for a Special Meeting on September 26, 2025, where stockholders will vote on a proposal to approve a **merger agreement** with Adifem, Inc., a wholly owned subsidiary of **Aditxt, Inc.**.  **[1618835_20250911LA71451:1]**

Evofem Biosciences Reports "Say Vagina" Campaign Impact and Merger Details

- Evofem Biosciences, Inc. entered into a **Sixth Amendment** to its Amended and Restated Agreement and Plan of Merger with Aditxt, Inc. and Adifem, Inc. on **August 26, 2025**.  **[1618835_0001641172-25-025530_ex2-1.htm:0]** **[1618835_0001641172-25-025530_form8-k.htm:1]** 
- This amendment updated the definition of "Unconverted Company Preferred Stock" to include Series G-1 Convertible Preferred Stock, clarified that the Company will assist in obtaining agreements to exchange Company convertible notes and purchase rights for an aggregate of **not more than 89,021 shares of Parent Preferred Stock**, and set limits for dissenting shares at **5,932,818** common shares and **202** preferred shares.  **[1618835_0001641172-25-025530_ex2-1.htm:0]** **[1618835_0001641172-25-025530_form8-k.htm:1]** 
- Additionally, on **August 22, 2025**, Evofem Biosciences, Inc. converted **$1,573,000** in senior secured convertible notes into **1,573 shares of Series G-1 Convertible Preferred Stock**.  **[1618835_0001641172-25-025530_form8-k.htm:1]**

Evofem Biosciences (EVFM)